Evidence map›Paper›PMID 36182995›Full record

ReviewEJNMMI radiopharmacy and chemistry2022

Highlight selection of radiochemistry and radiopharmacy developments by editorial board.

Jun Toyohara, Mohammed Al-Qahtani, Ya-Yao Huang, Emiliano Cazzola, Sergio Todde, Shozo Furumoto, Renata Mikolajczak, Clemens Decristoforo, Nic Gillings, Min Yang and 11 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EJNMMI radiopharmacy and chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Jun ToyoharaPET Radiopharmaceutical Sciences, Research Team for Neuroimaging, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.
Mohammed Al-QahtaniCyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh, Saudi Arabia.
Ya-Yao HuangMolecular Imaging Center, National Taiwan University, Taipei, Taiwan.
Emiliano CazzolaScientific Institute for Research, Hospitalization and Healthcare (IRCCS), Sacro Cuore-Don Calabria Hospital, Negrar (Vr), Italy.
Sergio ToddeUniversity of Milano-Bicocca, Tecnomed Foundation, Monza, Italy.
Shozo FurumotoCyclotron and Radioisotope Center (CYRIC), Tohoku University, Sendai, Japan.
Renata MikolajczakRadioisotope Centre POLATOM, National Centre for Nuclear Research (NCBJ), Otwock, Poland.
Clemens DecristoforoDepartment of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria.
Nic GillingsDepartment of Clinical Physiology and Nuclear Medicine, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark.
Min YangNHC Key Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
Raymond ReillyDepartment of Pharmaceutical Sciences, Leslie Dan Faculty of Pharmacy, University of Toronto, Toronto, ON, Canada.
Adriano DuattiDepartment of Chemical, Pharmaceutical and Agricultural Sciences, University of Ferrara, Ferrara, Italy.
Antonia DenkovaDepartment of Radiation Science and Technology, Delft University of Technology, Delft, The Netherlands.
Ralf SchirrmacherDepartment of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB, Canada.
Giuseppe CarlucciDepartment of Molecular and Medical Pharmacology, University of California, Los Angeles (UCLA), Los Angeles, CA, USA.
Yann SeimbilleDepartment of Radiology and Nuclear Medicine, Erasmus MC, University Medical Center Rotterdam, Rotterdam, The Netherlands.
Zhaofei LiuMedical Isotopes Research Center, Department of Radiation Medicine, School of Basic Medical Sciences, Peking University Health Science Centre, Beijing, China.
Beverley EllisManchester University NHS Foundation Trust, Manchester, UK.
Bart T CornelissenDepartment of Nuclear Medicine and Molecular Imaging, Groningen (UMCG), University Medical Center, University of Groningen, Groningen, The Netherlands.
Klaus KopkaHelmholtz-Zentrum Dresden-Rossendorf (HZDR), Institute of Radiopharmaceutical Cancer Research, Dresden, Germany. k.kopka@hzdr.de.ORCID http://orcid.org/0000-0003-4846-1271
Emerson BernardesEnergy and Nuclear Research Institute (IPEN-CNEN/SP), Cidade Universitária, São Paulo, Brazil.

Funding

Cancer Research UK 23970Medical Research Council MR/P018661/1Medical Research Council MR/S008209/1
6 · The paper itself

Abstract

backgroundThe Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. MAIN BODY: This commentary of highlights has resulted in 21 different topics selected by each coauthoring Editorial Board member addressing a variety of aspects ranging from novel radiochemistry to first in man application of novel radiopharmaceuticals.

conclusionTrends in radiochemistry and radiopharmacy are highlighted demonstrating the progress in the research field in various topics including new PET-labelling methods, FAPI-tracers and imaging, and radionuclide therapy being the scope of EJNMMI Radiopharmacy and Chemistry.

Indexed as

Highlight ArticlesNuclear MedicineRadiochemistryRadiopharmaceutical SciencesRadiopharmacyTrends in Radiopharmaceutical Sciences

Identifiers

PMID36182995
PMCPMC9526771

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.